1,846
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Upadacitinib in nail psoriasis: a case report

, , &
Article: 2246604 | Received 02 Apr 2023, Accepted 10 May 2023, Published online: 04 Sep 2023

References

  • Canal-García E, Bosch-Amate X, Belinchón I, et al. Nail psoriasis. Actas Dermosifiliogr. 2022;113(5):1–3. doi: 10.1016/j.ad.2022.01.006.
  • Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332–337. doi: 10.1111/bjd.17689.
  • Thomas L, Azad J, Takwale A. Management of nail psoriasis. Clin Exp Dermatol. 2021;46(1):3–8. doi: 10.1111/ced.14314.
  • Ji C, Wang H, Bao C, et al. Challenge of nail psoriasis: an update review. Clin Rev Allergy Immunol. 2021;61(3):377–402. doi: 10.1007/s12016-021-08896-9.
  • Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318. doi: 10.2340/00015555-3640.
  • Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther. 2020;10(1):29–42. doi: 10.1007/s13555-019-00347-w.
  • Singh S, Pradhan D, Puri P, et al. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61–71.
  • Abe M, Nishigori C, Torii H, et al. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial. J Dermatol. 2017;44(11):1228–1237. doi: 10.1111/1346-8138.13956.
  • Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961. doi: 10.1111/bjd.14018.
  • Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-Week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021;8(2):903–919. doi: 10.1007/s40744-021-00305-z.
  • Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4.
  • Grover C, Chaturvedi UK, Reddy BN. Role of nail biopsy as a diagnostic tool. Indian J Dermatol Venereol Leprol. 2012;78(3):290–298. doi: 10.4103/0378-6323.95443.
  • Pünchera J, Laffitte E. Treatment of severe nail lichen planus with baricitinib. JAMA Dermatol. 2022;158(1):107–108. doi: 10.1001/jamadermatol.2021.5082.